GSK plc Files 6-K on Share Transactions
Ticker: GLAXF · Form: 6-K · Filed: Sep 19, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 19, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 8 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transactions, 6-K, foreign-private-issuer
TL;DR
GSK plc filed a 6-K on 9/19/25 detailing share transactions.
AI Summary
GSK plc filed a Form 6-K on September 19, 2025, reporting transactions in its own shares during September 2025. The filing is a routine report for foreign private issuers and indicates GSK plc will file its annual reports under Form 20-F. The company is headquartered in London, UK.
Why It Matters
This filing provides transparency on GSK's activities related to its own stock, which can be relevant for investors monitoring share buybacks or issuances.
Risk Assessment
Risk Level: low — This is a routine filing reporting on share transactions, not indicating any new material risks or events.
Key Players & Entities
- GSK plc (company) — Registrant
- 001-15170 (company) — Commission File Number
- 79 New Oxford Street, London, WC1A 1DG (company) — Principal executive office address
- 20250919 (date) — Filing date
FAQ
What type of report is GSK plc filing?
GSK plc is filing a Form 6-K, which is a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934.
What is the primary subject of this 6-K filing?
The primary subject of this 6-K filing is 'Transaction in own shares'.
When was this Form 6-K filed?
This Form 6-K was filed on September 19, 2025.
Where is GSK plc's principal executive office located?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates that it files or will file annual reports under cover of Form 20-F.
Filing Stats: 1,905 words · 8 min read · ~6 pages · Grade level 4.1 · Accepted 2025-09-19 06:07:04
Filing Documents
- a9586z.htm (6-K) — 396KB
- 0001654954-25-010923.txt ( ) — 398KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: September 19, 2025         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc